Omniox Inc. Company Policy - Financial Conflict of Interest (FCOI) Policy

Scientific integrity and operational excellence are core values at Omniox. As recipients of Public Health Service (PHS)-sponsored research funds, a component of those core values is ensuring compliance with National Institutes of Health (NIH) and PHS requirements, including 42 CFR 50, Subpart F, "Responsibility of Applicants for Promoting Objectivity in Research for which PHS Funding is Sought." NIH policy (NIH Financial Conflict of Interest Guidelines) requires institutions subject to the requirements of the FCOI regulation to maintain an up-to-date, written, enforced FCOI policy that complies with the regulation, and to post the policy on their publicly accessible Web site. The overarching goal for this policy is to promote and encourage transparency in order to avoid distorting NIH funding decisions; NIH staff consider reports in light of other disclosures, e.g. other support, biographical sketch data, and foreign components, etc., and provide a holistic approach to award and risk management principles. This policy applies to all NIH grants and cooperative agreements, except Phase I SBIR/STTR applicants and recipients for budget periods beginning on or after October 1, 2020.

Omniox’s policy requires that each investigator, subrecipient, subgrantee and collaborator affiliated with Omniox, by NIH or any other applicable grant or contract, be in compliance with 42 CFR Part 50, Subpart F for PHS grants and cooperative agreements (and 45 CFR Part 94 for contracts). For purposes of financial disclosure only, this regulation also covers the spouse and dependent children of the investigator and key personnel.

Omniox's full policy can be found here. Any questions regarding FCOI policy may directed to